ALS, Denali
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
Hosted on MSN15h
Denali Fault Mystery Unveiled: A Geological Breakthrough Reshapes North America’s HistoryA 620-mile geological enigma that has baffled scientists for decades has finally been solved. The Denali Fault, a massive ...
To commemorate the 25th anniversary of Denali, GMC is offering customers a special 25th Anniversary Denali Package available ...
Stay connected with TTG Media's Noticeboard – your go-to space for industry updates, announcements, and community news from ...
Hosted on MSN1d
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trialThe primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price ...
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
HAL is planning a $70 million expansion over the next three years, including the construction of a new guestroom building.
Stock futures were rising modestly Tuesday, a day after tech shares helped lift the S&P 500 to its second straight gain.These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback